Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against
Gram-negative and Gram-positive bacteria. This agent is often used as the last line of
therapy for highly resistant Gram negative bacilli nosocomial infections. In common with
other beta-lactamase inhibitor, the main pharmacokinetic/pharmacodynamic (PK/PD) index that
correlates with the therapeutic efficacy is the time that concentrations in the tissue and
serum are above the MIC and administration by continuous infusion is the preferred mode of
administration to maximize this parameter.
However, in tropical countries, the stability of carbapenem antibiotics is an important
consideration when considering continuous infusion. Therefore, prolonged infusion may be a
useful mode of administration to maximize bactericidal activity. This study will demonstrate
the stability of imipenem in clinical use at room temperature in tropical countries.